Income statement
CAD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 1M |
| Gross Profit | -134K | -118K | 1M | 1M | 621K |
| Operating Income | -3M | -4M | -6M | -4M | -4M |
| EBITDA | -2M | -3M | -5M | -4M | -4M |
| Net Income | -2M | -6M | -6M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Maven Brands Inc. (TRLFF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +83.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +83.5%, free cash flow -72.6% with operating margin 0.0% and ROIC -56.6%. Stock Foundry combines TRLFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRLFF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRLFF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRLFF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
FY Net Income
-$4.0M
+28.0% YoY
Free Cash Flow
-$2.3M
+62.1% YoY
Revenue Growth
+0.0%
EPS Growth
+83.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 1M |
| Gross Profit | -134K | -118K | 1M | 1M | 621K |
| Operating Income | -3M | -4M | -6M | -4M | -4M |
| EBITDA | -2M | -3M | -5M | -4M | -4M |
| Net Income | -2M | -6M | -6M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 481K | 302K | 4M | 11M | 11M |
| Total Assets | 6M | 6M | 17M | 16M | 16M |
| Total Liabilities | 5M | 8M | 5M | 1M | 1M |
| Shareholder Equity | 396K | 396K | 12M | 15M | 15M |
| Total Debt | 5M | 6M | 6M | 4M | 0 |
| Net Debt | 4M | 6M | -583K | -7M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+0.0% YoY
Capital Expenditures
183K
+95.5% YoY
Free Cash Flow
2M
+62.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
438.8%
Debt / Equity
-4.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.